Based on the key indicators related to Tenax Therapeutics' liquidity, profitability, solvency, and operating efficiency, Tenax Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Tenax Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Other Liabilities is likely to rise to about 9.6 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 790.7 K in 2025. Key indicators impacting Tenax Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Tenax Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Tenax Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tenax Therapeutics.
Please note, the imprecision that can be found in Tenax Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tenax Therapeutics. Check Tenax Therapeutics' Beneish M Score to see the likelihood of Tenax Therapeutics' management manipulating its earnings.
Tenax Therapeutics Stock Summary
Tenax Therapeutics competes with Allarity Therapeutics, Virax Biolabs, Quoin Pharmaceuticals, Revelation Biosciences, and ZyVersa Therapeutics. Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. Tenax Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Tenax Therapeutics. It measures of how well Tenax is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Tenax Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Tenax had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Tenax Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Tenax Therapeutics's current stock value. Our valuation model uses many indicators to compare Tenax Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tenax Therapeutics competition to find correlations between indicators driving Tenax Therapeutics's intrinsic value. More Info.
Tenax Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At this time, Tenax Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tenax Therapeutics' earnings, one of the primary drivers of an investment's value.
Tenax Therapeutics Systematic Risk
Tenax Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tenax Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Tenax Therapeutics correlated with the market. If Beta is less than 0 Tenax Therapeutics generally moves in the opposite direction as compared to the market. If Tenax Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tenax Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tenax Therapeutics is generally in the same direction as the market. If Beta > 1 Tenax Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tenax Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tenax Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tenax Therapeutics growth as a starting point in their analysis.
Tenax Therapeutics March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tenax Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tenax Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tenax Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Tenax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tenax Therapeutics's daily price indicators and compare them against related drivers.
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.